1. A pilot trial of Cop 1 in exacerbationg-remitting multiple sclerosis;Bornstein;New England Journal of Medicine,1987
2. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis;Bornstein;Neurology,1991
3. The extension phase of the European-Canadian MRI study demonstrates a sustained effect of glatiramer acetate in relapsing-remitting multiple sclerosis;Comi,2001
4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of Glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing-remitting multiple sclerosis;Comi;Annals of Neurology,2001
5. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-center, randomized, double-blind, placebo-controlled study extended by open-label treatment;Comi;Neurology,1999